Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens
The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180 Streptococcus pneumoniae, 180 Haemophilus influenzae, 160 Moraxella catarrhalis and 190 Streptococcus pyogenes) isolated from patients with community-acqu...
Saved in:
| Published in: | International journal of antimicrobial agents Vol. 18; no. 4; pp. 379 - 382 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Elsevier B.V
01-01-2001
Amsterdam Elsevier New York, NY |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180
Streptococcus pneumoniae, 180
Haemophilus influenzae, 160
Moraxella
catarrhalis and 190
Streptococcus pyogenes) isolated from patients with community-acquired respiratory tract infections. MIC values for moxifloxacin, trovafloxacin were 0.25/0.25, 0.03/0.03, 0.06/0.03 and 0.125/0.0125 mg/l for
S. pneumoniae,
H. influenzae,
M. catharralis and
S. pyogenes. Based upon the MIC
90 values and the MIC distributions, moxifloxacin and trovafloxacin were the most active of the quinolones tested. They showed enhanced activity against Gram-positive organisms including penicillin non susceptible
S. pneumoniae strains. Moxifloxacin was also highly active against ciprofloxacin-resistant
S. pneumoniae strains. |
|---|---|
| AbstractList | The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180 Streptococcus pneumoniae, 180 Haemophilus influenzae, 160 Moraxella catarrhalis and 190 Streptococcus pyogenes) isolated from patients with community-acquired respiratory tract infections. MIC values for moxifloxacin, trovafloxacin were 0.25/0.25, 0.03/0.03, 0.06/0.03 and 0.125/0.0125 mg/l for S. pneumoniae, H. influenzae, M. catharralis and S. pyogenes. Based upon the MIC(90) values and the MIC distributions, moxifloxacin and trovafloxacin were the most active of the quinolones tested. They showed enhanced activity against Gram-positive organisms including penicillin non susceptible S. pneumoniae strains. Moxifloxacin was also highly active against ciprofloxacin-resistant S. pneumoniae strains. The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180 Streptococcus pneumoniae, 180 Haemophilus influenzae, 160 Moraxella catarrhalis and 190 Streptococcus pyogenes) isolated from patients with community-acquired respiratory tract infections. MIC values for moxifloxacin, trovafloxacin were 0.25/0.25, 0.03/0.03, 0.06/0.03 and 0.125/0.0125 mg/l for S. pneumoniae, H. influenzae, M. catharralis and S. pyogenes. Based upon the MIC sub(90) values and the MIC distributions, moxifloxacin and trovafloxacin were the most active of the quinolones tested. They showed enhanced activity against Gram-positive organisms including penicillin non susceptible S. pneumoniae strains. Moxifloxacin was also highly active against ciprofloxacin-resistant S. pneumoniae strains. The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180 Streptococcus pneumoniae, 180 Haemophilus influenzae, 160 Moraxella catarrhalis and 190 Streptococcus pyogenes) isolated from patients with community-acquired respiratory tract infections. MIC values for moxifloxacin, trovafloxacin were 0.25/0.25, 0.03/0.03, 0.06/0.03 and 0.125/0.0125 mg/l for S. pneumoniae, H. influenzae, M. catharralis and S. pyogenes. Based upon the MIC 90 values and the MIC distributions, moxifloxacin and trovafloxacin were the most active of the quinolones tested. They showed enhanced activity against Gram-positive organisms including penicillin non susceptible S. pneumoniae strains. Moxifloxacin was also highly active against ciprofloxacin-resistant S. pneumoniae strains. |
| Author | Lopez, H Lemme, L Ambler, J Vilches, V Scarano, S Sucari, A Smayevsky, J Stepanik, D Cardeñosa, O |
| Author_xml | – sequence: 1 givenname: H surname: Lopez fullname: Lopez, H email: 1hlopez@arnet.com.ar organization: Centro de Infectologı́a, Pacheco de Melo 3068 Buenos Aires 1425, Argentina – sequence: 2 givenname: V surname: Vilches fullname: Vilches, V organization: Centro de Infectologı́a, Pacheco de Melo 3068 Buenos Aires 1425, Argentina – sequence: 3 givenname: S surname: Scarano fullname: Scarano, S organization: Centro de Infectologı́a, Pacheco de Melo 3068 Buenos Aires 1425, Argentina – sequence: 4 givenname: D surname: Stepanik fullname: Stepanik, D organization: Centro de Infectologı́a, Pacheco de Melo 3068 Buenos Aires 1425, Argentina – sequence: 5 givenname: J surname: Smayevsky fullname: Smayevsky, J organization: CEMIC, Buenos Aires, Argentina – sequence: 6 givenname: L surname: Lemme fullname: Lemme, L organization: Bayer Pharmaceuticals, Buenos Aires, Argentina – sequence: 7 givenname: O surname: Cardeñosa fullname: Cardeñosa, O organization: Bayer Pharmaceuticals, Buenos Aires, Argentina – sequence: 8 givenname: J surname: Ambler fullname: Ambler, J organization: Bayer Pharmaceuticals, Buenos Aires, Argentina – sequence: 9 givenname: A surname: Sucari fullname: Sucari, A organization: Centro de Infectologı́a, Pacheco de Melo 3068 Buenos Aires 1425, Argentina |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14075702$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11691572$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0c9vFSEQB3Biauxr9U_QcNHoYRVYWODUmMZfSY0HeycszLaYXXgF9qXv6l_ubt-LPfbEYT4zTOZ7hk5iioDQa0o-UkK7T7-JZrxRQur3hH4ghFPdqGdoQ5VkjdS0PUGb_-QUnZXyhxAqWi5eoFNKO02FZBv09-c81uAg1gy41NnvcRpwvQUcIt6FmhOGnR1nW0OKa2lK92EY0711C7DR47TgjO_mENO4rFiwvbEhlopdmqY5hrrH1i3lDB5nKNuQbU15j7e23qYbiOUlej7YscCr43uOrr9-ub783lz9-vbj8vNV4zhjtfFUERg0V6TjrWL9oBUMrtPAGAGmbU-k99pLLaVmVFjZ895xIojj0hHXnqN3h7HbnO5mKNVMoTgYRxshzcVIxkSnuXgSUtV2LWvVAsUBupxKyTCYbQ6TzXtDiVlDMg8hmTUBQ6h5CMmsfW-OH8z9BP6x65jKAt4egS3OjkO20YXy6DiRQpLVXRwcLGfbBcimuADRgV-u7arxKTyxyj_oO7NL |
| CitedBy_id | crossref_primary_10_1016_S0399_077X_02_00017_3 crossref_primary_10_1016_j_aca_2005_04_053 crossref_primary_10_1111_j_1469_0691_2005_01216_x |
| Cites_doi | 10.1056/NEJM199907223410403 10.1128/AAC.41.1.101 10.1016/S0732-8893(00)00124-3 10.1128/AAC.41.7.1594 10.1128/AAC.43.11.2612 10.1093/jac/45.1.31 10.1093/jac/45.2.191 10.1093/jac/43.4.497 10.1086/319369 10.1016/S0924-8579(99)00143-0 10.1093/jac/44.6.749 10.1093/jac/40.suppl_1.11 |
| ContentType | Journal Article |
| Copyright | 2001 Elsevier Science B.V. 2002 INIST-CNRS |
| Copyright_xml | – notice: 2001 Elsevier Science B.V. – notice: 2002 INIST-CNRS |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL C1K 7X8 |
| DOI | 10.1016/S0924-8579(01)00419-8 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Bacteriology Abstracts (Microbiology B) |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1872-7913 |
| EndPage | 382 |
| ExternalDocumentID | 10_1016_S0924_8579_01_00419_8 11691572 14075702 S0924857901004198 |
| Genre | Multicenter Study Journal Article |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29J 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXUO ABBQC ABFNM ABFRF ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CJTIS CNWQP CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMG HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LCYCR LUGTX M29 M41 MO0 N9A O-L O9- OAUVE OD- OO. OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SIN SPCBC SSH SSI SSZ T5K UNMZH WUQ XPP Z5R ~G- ABPIF ABPTK IQODW AAHBH AAXKI ADVLN AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL C1K 7X8 |
| ID | FETCH-LOGICAL-c422t-d180ef948064382bf98efc69e220e29ab07dd9d79779215a7b4bc4050c47c0c3 |
| ISSN | 0924-8579 |
| IngestDate | Fri Oct 25 09:30:10 EDT 2024 Fri Oct 25 09:12:01 EDT 2024 Thu Sep 26 19:04:38 EDT 2024 Sat Sep 28 07:44:59 EDT 2024 Sun Oct 22 16:08:52 EDT 2023 Fri Feb 23 02:28:40 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Community acquired respiratory pathogens In vitro activity Moxifloxacin Respiratory disease Multicenter study Neisseriaceae In vitro Moraxella Biological activity Haemophilus influenzae Streptococcus pneumoniae Infection Pasteurellaceae Streptococcaceae Fluoroquinolone derivatives Minimum inhibitory concentration Bacteriosis Bacteria Micrococcales Streptococcus pyogenes Antibacterial agent Quinolone derivatives |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c422t-d180ef948064382bf98efc69e220e29ab07dd9d79779215a7b4bc4050c47c0c3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| PMID | 11691572 |
| PQID | 18363238 |
| PQPubID | 23462 |
| PageCount | 4 |
| ParticipantIDs | proquest_miscellaneous_72256945 proquest_miscellaneous_18363238 crossref_primary_10_1016_S0924_8579_01_00419_8 pubmed_primary_11691572 pascalfrancis_primary_14075702 elsevier_sciencedirect_doi_10_1016_S0924_8579_01_00419_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2001-01-01 |
| PublicationDateYYYYMMDD | 2001-01-01 |
| PublicationDate_xml | – month: 01 year: 2001 text: 2001-01-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | London Amsterdam New York, NY |
| PublicationPlace_xml | – name: Amsterdam – name: London – name: New York, NY – name: Netherlands |
| PublicationTitle | International journal of antimicrobial agents |
| PublicationTitleAlternate | Int J Antimicrob Agents |
| PublicationYear | 2001 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Garcı́a-Rodriguez, Trujillano, Fresnadillo, Iglesias (BIB17) 1999; I1 Hoogkamp-Korstanje, Roelofs-Willemse (BIB18) 2000; 45 Blondeau, Laskowski, Bjarnason, Stewart (BIB2) 2000; 14 Brueggemann, Kugler, Doern (BIB14) 1997; 41 Goldsmith, Moore, Murphy (BIB3) 1997; 40 Petersen, Bremm, Dalhoff (BIB1) 1999; 1 Deshpande, Jones (BIB15) 2000; 37 Chen, McGeer, Azavedo, Low (BIB11) 1999; 341 isolates. J. Antimicrob. Chemother. 43, Suppl B: 13–18. Thornsberry, Ogilvie, Holley, Sahm (BIB4) 1999; 43 Felmingham, Robbins, Leakey (BIB8) 1999; 1 Kayser, Santanam, Huf (BIB6) 1999; 1 National Committee for Clinical Laboratory Standards (NCCLS), 2000 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standards-fifth edition. M7-A5 Vol. 20 No. 2 Wyne P A: National Committee for Clinical Laboratory Standards. Thornsberry, Jones, Hickey, Mauriz, Khan, Sahm (BIB5) 1999; 44 Felmingham, Grüneberg (BIB13) 2000; 45 National Committee for Clinical Laboratory Standards (NCCLS), 2001. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; M100 S11 Vol 21 No. 1 Wyne P A: National Committee for Clinical Laboratory Standards. Buxbaum A, Straschil U, Moser C, Graninger W, Georgopoulos A, and the Austrian Survillance Network, 1999 Comparative susceptibility to penicillin and quinolones of 1385 Woodcock, Andrews, Boswell, Brendwald, Wise (BIB7) 1997; 41 Sanders (BIB16) 2001; 32 Thornsberry (10.1016/S0924-8579(01)00419-8_BIB5) 1999; 44 Hoogkamp-Korstanje (10.1016/S0924-8579(01)00419-8_BIB18) 2000; 45 Woodcock (10.1016/S0924-8579(01)00419-8_BIB7) 1997; 41 Felmingham (10.1016/S0924-8579(01)00419-8_BIB8) 1999; 1 10.1016/S0924-8579(01)00419-8_BIB12 10.1016/S0924-8579(01)00419-8_BIB10 Felmingham (10.1016/S0924-8579(01)00419-8_BIB13) 2000; 45 10.1016/S0924-8579(01)00419-8_BIB9 Blondeau (10.1016/S0924-8579(01)00419-8_BIB2) 2000; 14 Kayser (10.1016/S0924-8579(01)00419-8_BIB6) 1999; 1 Brueggemann (10.1016/S0924-8579(01)00419-8_BIB14) 1997; 41 Chen (10.1016/S0924-8579(01)00419-8_BIB11) 1999; 341 Sanders (10.1016/S0924-8579(01)00419-8_BIB16) 2001; 32 Petersen (10.1016/S0924-8579(01)00419-8_BIB1) 1999; 1 Deshpande (10.1016/S0924-8579(01)00419-8_BIB15) 2000; 37 Thornsberry (10.1016/S0924-8579(01)00419-8_BIB4) 1999; 43 Garcı́a-Rodriguez (10.1016/S0924-8579(01)00419-8_BIB17) 1999; I1 Goldsmith (10.1016/S0924-8579(01)00419-8_BIB3) 1997; 40 |
| References_xml | – volume: 1 start-page: 13 year: 1999 end-page: 26 ident: BIB1 article-title: The sintesis and in vitro and in vivo antibacterial activity of moxifloxacin (BAY 12-8039), a new 8-methoxyquinolone publication-title: Moxifloxacin in Practice contributor: fullname: Dalhoff – volume: 44 start-page: 749 year: 1999 end-page: 759 ident: BIB5 article-title: Resistance surveillance of publication-title: J. Antimicrob. Chemother. contributor: fullname: Sahm – volume: 37 start-page: 139 year: 2000 end-page: 142 ident: BIB15 article-title: Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States 1999 publication-title: Diagn. Microbiol. Infect. Dis. contributor: fullname: Jones – volume: 14 start-page: 45 year: 2000 end-page: 50 ident: BIB2 article-title: Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms publication-title: Int. J. Antimicrob. Agents contributor: fullname: Stewart – volume: 1 start-page: 27 year: 1999 end-page: 38 ident: BIB8 article-title: In vitro activity of moxifloxacin (BAY 12-8039), a novel 8-methoxyquinolone, compared with ofloxacin and other antibiotics publication-title: Moxifloxacin in Practice contributor: fullname: Leakey – volume: I1 start-page: 37 year: 1999 end-page: 48 ident: BIB17 article-title: In vitro activity of moxifloxacin against respiratory tract pathogens publication-title: Moxifloxacin in Practice contributor: fullname: Iglesias – volume: 41 start-page: 101 year: 1997 end-page: 106 ident: BIB7 article-title: In vitro activity of Bay 12-8039, a new fluoroquinolone publication-title: Antimicrob. Agents Chemother. contributor: fullname: Wise – volume: 45 start-page: 191 year: 2000 end-page: 203 ident: BIB13 article-title: The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections publication-title: J. Antimicrob. Chemother. contributor: fullname: Grüneberg – volume: 1 start-page: 39 year: 1999 end-page: 48 ident: BIB6 article-title: In vitro activity of moxifloxacin against invasive pneumococcal strains compared with other antimicrobials publication-title: Moxifloxacin in Practice contributor: fullname: Huf – volume: 32 start-page: S1 year: 2001 end-page: S8 ident: BIB16 article-title: Mechnisms responsible for cross-resistence and dichotomus resistence among the quinolones publication-title: Clin. Infect. Dis. contributor: fullname: Sanders – volume: 43 start-page: 2612 year: 1999 end-page: 2623 ident: BIB4 article-title: Survey of susceptitibilities of publication-title: Antimicrob. Agents Chemother. contributor: fullname: Sahm – volume: 341 start-page: 233 year: 1999 end-page: 239 ident: BIB11 article-title: Decreased susceptibility of publication-title: New Engl. J. Med. contributor: fullname: Low – volume: 45 start-page: 31 year: 2000 end-page: 39 ident: BIB18 article-title: Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates publication-title: J. Antimicrob. Chemother. contributor: fullname: Roelofs-Willemse – volume: 41 start-page: 1594 year: 1997 end-page: 1597 ident: BIB14 article-title: In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against publication-title: Antimicrob. Agents Chemother. contributor: fullname: Doern – volume: 40 start-page: 11 year: 1997 end-page: 18 ident: BIB3 article-title: Pneumococcal resistance in the UK publication-title: J. Antimicrob. Chemother. contributor: fullname: Murphy – volume: 341 start-page: 233 year: 1999 ident: 10.1016/S0924-8579(01)00419-8_BIB11 article-title: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada publication-title: New Engl. J. Med. doi: 10.1056/NEJM199907223410403 contributor: fullname: Chen – volume: 41 start-page: 101 year: 1997 ident: 10.1016/S0924-8579(01)00419-8_BIB7 article-title: In vitro activity of Bay 12-8039, a new fluoroquinolone publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.41.1.101 contributor: fullname: Woodcock – volume: 37 start-page: 139 issue: 2 year: 2000 ident: 10.1016/S0924-8579(01)00419-8_BIB15 article-title: Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States 1999 publication-title: Diagn. Microbiol. Infect. Dis. doi: 10.1016/S0732-8893(00)00124-3 contributor: fullname: Deshpande – volume: 41 start-page: 1594 year: 1997 ident: 10.1016/S0924-8579(01)00419-8_BIB14 article-title: In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.41.7.1594 contributor: fullname: Brueggemann – volume: 1 start-page: 13 year: 1999 ident: 10.1016/S0924-8579(01)00419-8_BIB1 article-title: The sintesis and in vitro and in vivo antibacterial activity of moxifloxacin (BAY 12-8039), a new 8-methoxyquinolone contributor: fullname: Petersen – volume: 43 start-page: 2612 year: 1999 ident: 10.1016/S0924-8579(01)00419-8_BIB4 article-title: Survey of susceptitibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective US study publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.43.11.2612 contributor: fullname: Thornsberry – volume: 45 start-page: 31 year: 2000 ident: 10.1016/S0924-8579(01)00419-8_BIB18 article-title: Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/45.1.31 contributor: fullname: Hoogkamp-Korstanje – volume: 1 start-page: 39 year: 1999 ident: 10.1016/S0924-8579(01)00419-8_BIB6 article-title: In vitro activity of moxifloxacin against invasive pneumococcal strains compared with other antimicrobials contributor: fullname: Kayser – volume: 45 start-page: 191 year: 2000 ident: 10.1016/S0924-8579(01)00419-8_BIB13 article-title: The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/45.2.191 contributor: fullname: Felmingham – ident: 10.1016/S0924-8579(01)00419-8_BIB12 doi: 10.1093/jac/43.4.497 – ident: 10.1016/S0924-8579(01)00419-8_BIB9 – volume: 32 start-page: S1 year: 2001 ident: 10.1016/S0924-8579(01)00419-8_BIB16 article-title: Mechnisms responsible for cross-resistence and dichotomus resistence among the quinolones publication-title: Clin. Infect. Dis. doi: 10.1086/319369 contributor: fullname: Sanders – volume: I1 start-page: 37 year: 1999 ident: 10.1016/S0924-8579(01)00419-8_BIB17 article-title: In vitro activity of moxifloxacin against respiratory tract pathogens contributor: fullname: Garcı́a-Rodriguez – volume: 14 start-page: 45 year: 2000 ident: 10.1016/S0924-8579(01)00419-8_BIB2 article-title: Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms publication-title: Int. J. Antimicrob. Agents doi: 10.1016/S0924-8579(99)00143-0 contributor: fullname: Blondeau – volume: 44 start-page: 749 year: 1999 ident: 10.1016/S0924-8579(01)00419-8_BIB5 article-title: Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997–1998 publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/44.6.749 contributor: fullname: Thornsberry – ident: 10.1016/S0924-8579(01)00419-8_BIB10 – volume: 40 start-page: 11 issue: Suppl. A year: 1997 ident: 10.1016/S0924-8579(01)00419-8_BIB3 article-title: Pneumococcal resistance in the UK publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/40.suppl_1.11 contributor: fullname: Goldsmith – volume: 1 start-page: 27 year: 1999 ident: 10.1016/S0924-8579(01)00419-8_BIB8 article-title: In vitro activity of moxifloxacin (BAY 12-8039), a novel 8-methoxyquinolone, compared with ofloxacin and other antibiotics contributor: fullname: Felmingham |
| SSID | ssj0015345 |
| Score | 1.673611 |
| Snippet | The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180
Streptococcus... The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180 Streptococcus... |
| SourceID | proquest crossref pubmed pascalfrancis elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 379 |
| SubjectTerms | Anti-Infective Agents - pharmacology Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Aza Compounds Bacteria - drug effects Biological and medical sciences Ciprofloxacin - pharmacology Community acquired respiratory pathogens Community-Acquired Infections - microbiology Fluoroquinolones Haemophilus influenzae - drug effects Humans In vitro activity Levofloxacin Medical sciences Microbial Sensitivity Tests Moraxella (Branhamella) catarrhalis - drug effects Moxifloxacin Naphthyridines - pharmacology Ofloxacin - pharmacology Pharmacology. Drug treatments Quinolines Respiratory Tract Infections - microbiology Streptococcus pneumoniae - drug effects Streptococcus pyogenes - drug effects |
| Title | Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens |
| URI | https://dx.doi.org/10.1016/S0924-8579(01)00419-8 https://www.ncbi.nlm.nih.gov/pubmed/11691572 https://search.proquest.com/docview/18363238 https://search.proquest.com/docview/72256945 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6TUhICMG4lcvwA5pAXUbi3OzHCYoGD2jSKrS3yEmcKWIkZWnR-sov5xw7iVNGxUXiJWpTx3Z1vhyf-yHkRRD4hRAqc9wsBQXFjyJHpspzWFwIrsKQSe09Pz6NP57xt9NgOhp1NVztvf9KabgHtMbM2b-gdj8p3IDPQHO4AtXh-kd01xm1OuSyrR3bRQGU1eRbubisBwW-tXO9viqLi_pKZqWJS9YpWZOvyxIt7sAIJ_JcliBEYvQ55pKA1C4zjB9WmPhiHfXY27iGbTVDeXfd4DgoUwEELb-UugoUVis470pK6eCgem7s2r0b61N5gY291oJy0XUkdeNwa77FmDVZlZ9tKHNn0PB-Mmhcz7Qx5koWODw0jWcOlWHWPGZYbtP_NTe3pgrNmv3uWfPNtDy6doAYW8ZpvxyI-djKQGBdMuFwe2r2sYx6LA51PT2Ib5EdBlwPmO7O0fvp2YfeqRX6umd2P7dNKHttF3zpeq_axTaJSrfmsoEXuDCdVzarRlpEmt0ht1vdhh4ZUN4lI1Xtkhum2-lql-yfmDLpqwM6s1l_zQHdpye2gPrqHvk-wDDVGKZ1QQGWtKyoxjC1GMafhhimgGGqMUwthmmLYdpjmHYYpgMM0x7D98ns3XT25thpe4U4WcDYwsk97qpCBBxFbM5S5DRFFgnFmKuYkKkb57nIY1B3BEi5Mk6DNANlxc2COHMz_wHZrmA_jwhNVc6iDPsugK4ReqkoQCZQEQe9ykvhOiaHHVWSuakIk9hQSSBjgmRMXC_RZEz4mPCOdkkr1hpxNQHQ_e7RvTVa2wUDEPVj3MzzjvgJnAvo7JOVqpdNAkc1_AGfbx4Rw1EeiSAck4cGNXZ2rKAVxuzxv-_8Cblp3-2nZHtxuVTPyFaTL_fa1-IH7B_xxg |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multicentre+study+of+the+in+vitro+evaluation+of+moxifloxacin+and+other+quinolones+against+community+acquired+respiratory+pathogens&rft.jtitle=International+journal+of+antimicrobial+agents&rft.au=Lopez%2C+H&rft.au=Vilches%2C+V&rft.au=Scarano%2C+S&rft.au=Stepanik%2C+D&rft.date=2001-01-01&rft.pub=Elsevier+B.V&rft.issn=0924-8579&rft.eissn=1872-7913&rft.volume=18&rft.issue=4&rft.spage=379&rft.epage=382&rft_id=info:doi/10.1016%2FS0924-8579%2801%2900419-8&rft.externalDocID=S0924857901004198 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0924-8579&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0924-8579&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0924-8579&client=summon |